News & Events
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019
The company’s lead product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States.
READ MORECrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
2018 was a transformative year for Crinetics, highlighted by our successful initial public offering in July and the progress of our pipeline programs for rare endocrine diseases,” said Scott Struthers, Ph. D. , Founder and Chief Executive Officer of Crinetics.
READ MORECrinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
Crinetics today announced that Scott Struthers, Ph. D. , Founder and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 1 p.
READ MORECrinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Crinetics today announced that Scott Struthers, Ph. D. , Founder and Chief Executive Officer, will present at the 37th Annual J.
READ MORECrinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Following the success of our July 2018 initial public offering, the Crinetics team is on track for the initiation of our Phase 2 EVOLVE and Phase 2 EDGE clinical trials in early 2019 for our lead product candidate, CRN00808, in acromegaly,” said Scott Struthers, Ph. D. , Founder and Chief Executive Officer of Crinetics.
READ MORECrinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology
Crinetics today announced that Scott Struthers, Ph. D. , Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York on Tuesday, October 2, 2018 at 11:00 a.
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals today announced that Scott Struthers, Ph. D. , Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York on Tuesday, October 2, 2018 at 11:00 a.
READ MORECrinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Crinetics today announced the closing of its initial public offering of 6,900,000 shares of common stock, which includes the exercise in full of the underwriters' option to purchase 900,000 additional shares of common stock, at a public offering price of $17. 00 per share. The aggregate gross proceeds to Crinetics from the offering were $117.
READ MORECrinetics Pharmaceuticals Announces Pricing of Initial Public Offering
Crinetics today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $17. 00 per share. All of the shares are being offered by Crinetics.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
